Overall, according with a panel of experts appointed by the ELN in 2011, the presence of mutations can be investigated with NGS technique and recommended it for detecting BCR::ABL1 KD mutations in CML patients with a “failure” or “warning” response to TKI therapy [21]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.